IPO Filing Date: Nov. 12, 2010
Expected IPO Date: Feb. 7, 2011
Amount of Proceeds Sought: ~$75 millionExpected Offering Price: $12 to $14 Expected Number of Shares to Be Sold: ~ 5.8 million Use of Proceeds: To fund phase 3 development of lead, post-surgery pain treatment product ARX-01; working capital; and other general corporate purposes.
Expected Ticker Symbol: ACRX (ACRX) (NASDAQ)
Lead Underwriters: Piper Jaffray (PJC) Co-Managers: Canaccord Genuity, Cowen and Company (COWN), JMP Securities (JMP)
About the Company: AcelRx is a drug company that focuses on developing and commercializing pain treatment therapies. Currently it has three products in the pipeline, but not yet on the market. The lead product is post-surgery pain treatment product ARX-01. Its ARX-02 product treats pain in cancer patients and its ARX-03 product treats pain and anxiety caused by painful physician procedures. The company aims to bring its products to market amid a burgeoning, global post-surgical pain market. According to AcelRx, the post-operative pain market in the U.S., Europe and Japan is expected to reach $6.5 billion by 2018. Given that the company isn't selling any products yet, it hasn't generated any revenue since it was founded in Jul. 2005. AcelRx has experienced significant net losses every year since its inception. It could fail as a business if the company doesn't successfully commercialize its products. Competitors: The main competitor against the company's ARX-01 product is the widely-used IV PCA pump. Leading manufacturers of IV PCA pumps include Hospira (HSP), CareFusion (CFN), Baxter International (BAX) and Smiths Medical (SMGZY). Potential competitors for ARX-01 that are currently also being developed include Ionsys, which was originally developed by Johnson & Johnson (JNJ) subsidiaries. Potential competitors for the company's ARX-02 product include Actiq and Fentora, made by Cephalon (CEPH); Onsolis, made by BioDelivery Sciences International (BDSI), and Abstral, made by ProStrakan Group (PKNGF). IPO Scorecard:
Actual IPO Date: Feb. 11 Actual Proceeds Raised: $40 million Actual Offering price: $5 Actual Number of Shares Sold: 8 million
First Day Closing Price: $4.55 IPO First Day Return: -9
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV